Advertisement


Arlene O. Siefker-Radtke, MD, on Metastatic Urothelial Carcinoma: New Data on Erdafitinib and Cetrelimab From the NORSE Study

2023 ASCO Annual Meeting

Advertisement

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses the combination of erdafitinib and cetrelimab, which demonstrated clinically meaningful activity and was well tolerated in cisplatin-ineligible patients with metastatic urothelial carcinoma and fibroblast growth factor receptor alterations (Abstract 4504).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Arlene O. Siefker-Radtke: The NORSE clinical trial was designed to study erdafitinib and erdafitinib in combination with cetrelimab in the frontline treatment of patients with metastatic urothelial tumors. The premise behind this trial was that the FGF-altered tumor, which has been associated with an immunologically cold tumor microenvironment, may benefit from the combination of erdafitinib with cetrelimab, a checkpoint inhibitor that targets PD-1 expression found on tumor. This clinical trial was a randomized, yet non-comparative cohort trial similar to what has been used with other clinical trials in this space. Approximately 45 patients were randomized in each arm, erdafitinib only, and erdafitinib plus cetrelimab. Patients must have been ineligible for cisplatin-based chemotherapy and not received prior treatment for their urothelial carcinoma. When we look at the results, erdafitinib only had an objective response rate that was around 45%, similar to what has been reported on other clinical trials of erdafitinib in the second-line space. The combination of erdafitinib plus cetrelimab was associated with an objective response rate of around 55%, with a trend toward more and deeper responses, regardless of PD-L1 expression levels that were observed in the tumor tissue. We also saw benefit in progression-free survival with erdafitinib having a 5.5 month progression-free survival similar to second-line strategies and the combination of erdafitinib with cetrelimab having a progression-free survival of around 11 months. This translated to an overall survival of 16 months with erdafitinib only, and the combination of erdafitinib with cetrelimab had a median overall survival of 20.8 months, which is similar to other targeted strategies in the frontline cisplatin-ineligible space. So, as a result of this trial, we see evidence of efficacy and benefit with erdafitinib in the single-agent space. We also see a potential for benefit with combination therapy that's worth further study. Not only did we see an improvement in overall survival that was statistically significant, we also saw an improvement in progression-free survival with erdafitinib coming in at 5.5 months, and single-agent chemotherapy having a progression free survival rate that was half that amount. This also translated to an improved objective response rate. Erdafitinib had an objective response rate of 45% compared to 11% observed with single-agent taxane. So, erdafitinib showed evidence of clinical benefit by objective responses, progression-free survival, and median overall survival in the treatment of urothelial carcinoma. The toxicity profile was also quite similar to what has been observed with other FGF-targeted strategies with hyperphosphatemia, hand-foot syndrome, and mucositis as being the most frequent toxicities. We saw Central serous retinopathy in approximately 20% of patients, and this was with use of screening, with baseline screening with an ophthalmology exam and optical coherence tomography testing at baseline, and monthly, for the first four months. So, in all, erdafitinib is here to stay with improved benefit, improved response rate, progression-free survival, and overall survival, providing hope for the longevity of our bladder cancer patients with metastatic urothelial tumors.

Related Videos

Lung Cancer

Nagla Abdel Karim, MD, on Small Cell Lung Cancer: SWOG S1929 Results on Atezolizumab Plus Talazoparib

Nagla Abdel Karim, MD, of the Inova Schar Cancer Institute, University of Virginia, discusses phase II data showing that maintenance atezolizumab plus talazoparib improved progression-free survival in Schlafen-11–selected patients with extensive-stage small cell lung cancer. This study demonstrated the feasibility of conducting biomarker-selected trials in this disease, paving the way for future evaluation of novel therapies in selected populations (Abstract 8504).

Kidney Cancer
Immunotherapy

Rana R. McKay, MD, and Brian I. Rini, MD, on Clear Cell RCC: New Data From KEYNOTE-426 on Pembrolizumab Plus Axitinib vs Sunitinib

Rana R. McKay, MD, of the University of California, San Diego, and Brian I. Rini, MD, of Vanderbilt-Ingram Cancer Center, discuss the 5-year follow-up results with the combination of a checkpoint inhibitor plus a VEGFR tyrosine kinase inhibitor as first-line treatment for patients with advanced clear cell renal cell carcinoma (RCC). Pembrolizumab plus axitinib continued to demonstrate improved survival outcomes as well as overall response rate vs sunitinib for patients with previously untreated disease (Abstract LBA4501).

Skin Cancer
Immunotherapy

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Results From CheckMate 358 on Nivolumab With or Without Ipilimumab

Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses phase I/II results on the efficacy of nivolumab with or without ipilimumab in patients with recurrent or metastatic Merkel cell carcinoma. The study found that, for this rare and aggressive skin cancer, nivolumab showed clinical activity in advanced disease. However, these results from CheckMate 358 do not suggest an additional benefit with ipilimumab added to nivolumab (Abstract 9506).

 

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, on Localized Prostate Cancer: Prognostic Impact of PSA Nadir

Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, both of Dana-Farber Cancer Institute, discuss an individual patient-data analysis of randomized trials from the ICECAP collaborative. A PSA nadir of ≥ 0.1 ng/mL within 6 months after radiotherapy completion was prognostic for prostate cancer–specific, metastasis-free, and overall survival in patients receiving radiotherapy plus androgen-deprivation therapy for localized prostate cancer. These findings may help identify patients for therapy de-escalation trials (Abstract 5002).

Gynecologic Cancers
Immunotherapy

Bradley J. Monk, MD, on Cervical Cancer: Findings on Pembrolizumab Plus Chemotherapy

Bradley J. Monk, MD, of the University of Arizona, Phoenix, and Creighton University, discusses phase III findings from the KEYNOTE-826 study of overall survival results in patients with persistent, recurrent, or metastatic cervical cancer. Study participants received first-line treatment of pembrolizumab plus chemotherapy, with or without bevacizumab, which reduced the risk of death by up to 40% in three different subsets of patients (Abstract 5500).

Advertisement

Advertisement




Advertisement